NeuroRx and Relief Therapeutics announce enrollment of 150 patients in phase 2b/3 trial of RLF-100? for Critical COVID-19 with Respiratory Failure
RADNOR, Pa.?and?GENEVA,?Nov. 13, 2020?/PRNewswire/ --?NeuroRx, Inc. and Relief Therapeutics Holdings AG (SIX:RLF,OTCBB:RLFTF) ("Relief") announced that as of today, 150 patients (out of a targeted enrollment of 165) have been enrolled in the ongoing phase?2b/3 trial of RLF-100? (aviptadil) for treating respiratory failure in patients with Critical COVID-19. Respiratory failure is defined, according to FDA guidance, as the need for intensive care with mechanical ventilation, non-invasive ventilation, or high-flow nasal oxygen in order to sustain adequate levels of blood oxygen. So far, no drug-related Serious Adverse Events have been reported.
CORPORATE CONTACTS |
|
NeuroRx, Inc.? |
Relief Therapeutics Holdings SA? |
Jonathan C. Javitt, M.D., MPH? |
Raghuram (Ram) Selvaraju, Ph.D., MBA? |
Chairman and Chief Executive Officer?? |
Chairman of the Board? |
MEDIA CONTACT?? |
|
NeuroRx (United States):?? |
Relief (Europe): |
David Schull?? |
Anne Hennecke / Brittney Sojeva |
Russo Partners, LLC?? |
MC Services AG |
858-717-2310 |
+49 (0) 211-529-252-14 |
INVESTOR RELATIONS |
|
NeuroRx (United States) |
Relief (Europe): |
Brian Korb |
Anne Hennecke / Brittney Sojeva |